Wegovy Reimbursement: How NHS Coverage Works and What It Means for You

Step 1, Does NICE actually recommend NHS funding for Wegovy?

Yes, but with conditions that rule out most people at the moment. Wegovy (semaglutide) was appraised by NICE in TA875, published in March 2023. The recommendation covers adults with a BMI of 35 or above and at least one weight-related comorbidity, for example, type 2 diabetes, high blood pressure, cardiovascular disease or obstructive sleep apnoea. Thresholds sit around 2.5 kg/m² lower for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK clinical guidance.

There are two further conditions that narrow reimbursement further still. First, treatment must be delivered within a specialist weight management service with multidisciplinary support, not simply a GP issuing a prescription in isolation. Second, NICE sets a maximum treatment duration of two years; if someone loses less than 5% of their body weight after six months on the maintenance dose, continuing treatment should be reviewed. You can read the recommendation wording directly in NICE's full appraisal of semaglutide (TA875).

What this means in practice: passing the BMI and comorbidity threshold gets you into the queue. It does not guarantee a funded prescription quickly.

Step 2 (Understanding the NHS rollout and why waiting lists still matter

England's NHS is introducing tirzepatide (Mounjaro) through a phased primary-care rollout, but Wegovy on the NHS has historically been routed through specialist services under TA875) and those services carry long waiting lists in most areas. Commissioning is handled locally by Integrated Care Boards, so availability genuinely differs between, say, Greater Manchester and rural Lincolnshire.

Scotland, Wales and Northern Ireland set their own access criteria. NHS Inform Scotland publishes guidance on weight-loss medicines and devolved access. If you live outside England, the information on this page is a starting point, not the full picture, your local health board's criteria apply.

For anyone exploring what the dose journey looks like once treatment does start, the Wegovy dose increments page sets out the titration schedule factually. Knowing it in advance helps set realistic expectations about how treatment progresses over the first several months.

Step 3, What happens if you don't qualify for NHS reimbursement yet?

The honest answer is that most adults who are clinically suitable under the licensed criteria (BMI 30 or above, or 27+ with a weight-related condition) do not currently meet the narrower NHS reimbursement threshold of BMI 35 plus a comorbidity within a specialist service. For them, private prescription is the only legal route available now.

Private treatment through a GPhC-registered pharmacy involves no referral and no waiting list. You complete a clinical consultation, a prescriber reviews your information the same day, and if you are clinically suitable, treatment can be dispatched quickly. The cost falls entirely to you, there is no insurance reimbursement mechanism for prescription weight-loss medicines in the UK private sector at present. If you want to understand what that costs and what it does and does not include, the Wegovy pricing page covers the market context honestly, including what headline prices sometimes leave out.

It is also worth noting that Wegovy received MHRA approval for a higher 7.2mg maintenance dose in early 2026, with a dedicated single-dose pen approved in April 2026. Whether that option suits you is a clinical decision; a prescriber working through a full weight management assessment is best placed to advise.

Step 4, Checking your eligibility and taking the private route if NHS access isn't open to you

If you want to know whether you currently qualify for NHS-funded Wegovy, the most direct route is asking your GP. They can check your BMI, review your comorbidities and refer you to a specialist service if you meet the criteria. That referral does not guarantee a short wait.

For those choosing the private route, the process at a regulated pharmacy starts with a consultation (free at nume) reviewed by a GPhC-registered Independent Prescriber. Photo-ID verification and live weight confirmation are part of the process; a prescriber checks your full medical picture before any prescription is issued. Our clinical team and the safety steps behind every consultation are described on the about page. If you have questions before starting, the FAQs cover the most common ones.

One practical note: Wegovy injections require refrigerated storage between 2°C and 8°C. Many patients keep their pen in the fridge door alongside everyday items, sensible enough, but always check the Patient Information Leaflet for the exact room-temperature window before travelling, and if you are thinking about digestive comfort during treatment, it is worth reading up on the best fiber supplement to take alongside Wegovy. A private prescription does not change those storage requirements.

Semaglutide in a broader context (including how it is regulated and what the advertising rules mean for how you find information online) is covered on the semaglutide advertising page. When you are ready to speak to a prescriber, start your free consultation with the nume clinical team.